HMG
FDA ApprovedAlso known as: Human Menopausal Gonadotropin, Menotropins, hMG, Menopur, Pergonal, Repronex, HP-hMG
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.
Research Statistics
FDA-approved fertility hormone with 60+ years of global clinical use; FSH/LH mechanism is textbook reproductive endocrinology with extensive multinational trial data.
Research Dossier
Overview
What is HMG and what does the research say?
Mechanism of Action
HMG provides both FSH and LH activity, the two “master hormones” required for reproduction. Its mechanisms are established through decades of clinical use and extensive human trials.
How It Works (Simplified)
HMG delivers both gonadotropins needed for reproductive function:
FSH component binds to granulosa cell receptors, activating cAMP/PKA signaling to stimulate follicle growth and aromatase expression for estrogen synthesis.
LH activity stimulates theca cells to produce androgens, which granulosa cells convert to estrogens - the “two-cell, two-gonadotropin” model.
In men, FSH supports Sertoli cells for spermatogenesis while LH activity stimulates Leydig cells to produce testosterone - restoring reproductive function.
Combined FSH/LH activity may improve oocyte and embryo quality compared to FSH alone, particularly in IVF cycles with standard insemination.
Scientific Pathways
FSH Receptor Pathway (Follicular Development)
FSH binds FSHR (granulosa cells) → Galphas → adenylyl cyclase → cAMP → PKA
↓
Aromatase expression + follicle growthLH Receptor Pathway (Steroidogenesis)
LH/hCG binds LHCGR (theca/Leydig cells) → Galphas → cAMP → PKA
↓
Androgen synthesis → Testosterone productionKey Research: Cochrane Review (van Wely et al. 2011) of 42 RCTs with 9,606 women demonstrated HMG associated with significantly higher live birth rates than recombinant FSH. PMID:21328277
Important Limitations
- Primary safety concern is Ovarian Hyperstimulation Syndrome (OHSS), occurring in 3-5% of cycles
- Requires careful monitoring with estradiol levels and ultrasound
- Multiple pregnancy risk (20-30% twins in ovulation induction without IVF)
- Urinary-derived product; batch-to-batch variation possible despite purification
- Contraindicated in primary ovarian failure, hormone-dependent tumors, and pregnancy
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial follicular recruitment phase. HMG administration typically begins cycle day 2-3. FSH component rescues cohort of antral follicles from atresia. Baseline ultrasound confirms no residual cysts.
Active follicular growth phase. Dominant follicles emerge and grow 1-2mm daily. Estradiol rises progressively. Dose adjustments based on ovarian response. Monitoring with serial ultrasound and estradiol levels.
Final maturation phase. Lead follicles reach 17-20mm diameter. Estradiol typically 200-300 pg/mL per mature follicle. hCG trigger administered when criteria met. Egg retrieval 34-36 hours after trigger.
In hypogonadotropic hypogonadism, hCG monotherapy first normalizes testosterone (typically 3 months). HMG then added at 75-150 IU 2-3x weekly. Spermatogenesis initiation takes 3-6 months; optimal sperm counts may require 12-24 months.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate HMG product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining HMG with other peptides. Based on published research and mechanistic considerations.
HCG
SynergisticStandard clinical combination. HMG provides FSH/LH for follicular development while hCG triggers final oocyte maturation. Well-established protocol in fertility medicine with decades of combined use data.
Gonadorelin
SynergisticGnRH agonists used in long protocols to prevent premature LH surge during HMG stimulation. Established clinical combination for controlled ovarian hyperstimulation.
Kisspeptin
CompatibleKisspeptin acts upstream on GnRH neurons. Emerging research on kisspeptin for oocyte maturation trigger as alternative to hCG. No direct interaction concerns with HMG.
Growth-Hormone
CompatibleGH co-treatment studied as adjuvant in poor responders to gonadotropins. May improve ovarian response to HMG in certain patient populations. Limited interaction data.
Semaglutide
CautionGLP-1 agonists affect reproductive hormones. Weight loss from semaglutide may improve fertility outcomes, but direct interactions with gonadotropins not well characterized.
Testosterone
AvoidExogenous testosterone suppresses gonadotropin axis and impairs spermatogenesis. Contraindicated during HMG therapy for male infertility; must discontinue testosterone before initiating HMG.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare HMG
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
IGF-1 LR3
Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor 1 Long R3
A modified form of IGF-1 with an extended half-life due to reduced binding protein affinity. Used primarily in research for muscle growth and metabolic effects. Not approved for human use; significant safety concerns exist.